Adipose Tissue and Umbilical Cord Tissue: Potential Sources of Mesenchymal Stem Cells for Liver Fibrosis Treatment
Mesenchymal stem cells (MSCs) are potential alternatives for liver fibrosis treatment; however, their optimal sources remain uncertain. This study compares the ex-vivo expansion characteristics of MSCs obtained from adipose tissue (AT) and umbilical cord (UC) and assesses their therapeutic potential...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical and experimental hepatology 2024-07, Vol.14 (4), p.101364-101364, Article 101364 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 101364 |
|---|---|
| container_issue | 4 |
| container_start_page | 101364 |
| container_title | Journal of clinical and experimental hepatology |
| container_volume | 14 |
| creator | Ghufran, Hafiz Azam, Maryam Mehmood, Azra Umair, Muhammad Baig, Maria T. Tasneem, Saba Butt, Hira Riazuddin, Sheikh |
| description | Mesenchymal stem cells (MSCs) are potential alternatives for liver fibrosis treatment; however, their optimal sources remain uncertain. This study compares the ex-vivo expansion characteristics of MSCs obtained from adipose tissue (AT) and umbilical cord (UC) and assesses their therapeutic potential for liver fibrosis treatment.
Since MSCs from early to mid-passage numbers (P2–P6) are preferable for cellular therapy, we investigated the growth kinetics of AT-MSCs and UC-MSCs up to P6 and evaluated their therapeutic effects in a rat model of liver fibrosis induced by diethylnitrosamine.
Results from the expansion studies demonstrated that both cell types exhibited bona fide characteristics of MSCs, including surface antigens, pluripotent gene expression, and differentiation potential. However, AT-MSCs demonstrated a shorter doubling time (58.2 ± 7.3 vs. 82.3 ± 4.3 h; P |
| doi_str_mv | 10.1016/j.jceh.2024.101364 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2942190309</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0973688324000215</els_id><sourcerecordid>2942190309</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-cbd998b7eac04d4097ef138e3ab713e06733d67a78d775b81f6274e203c7bb043</originalsourceid><addsrcrecordid>eNp9kE1rGzEQhkVoaIyTP9BD0LGXdfVlabf0YkydFhwSiHMW-pglMruWK-0G_O-rxU6PncvAO--8zDwIfaFkQQmV3_aLvYO3BSNMTAKX4grNGKO84mLJP6EZaRSvZF3zG3SX856UksVM2Gd0w2shmiWRM5RWPhxjBrwLOY-AzcHj196GLjjT4XVM_jL5jp_jAIchFPkljslBxrHFj5Dh4N5O_SQP0OM1dF3GbUx4G94h4U2wKeaQ8S6BGfqScIuuW9NluLv0OXrd_Nytf1Xbp4ff69W2cnwph8pZ3zS1VWAcEV6Ud6ClvAZurKIciFSce6mMqr1SS1vTVjIlgBHulLVE8Dn6es49pvhnhDzoPmRXzjMHiGPWrBGMNoSTpljZ2erKrTlBq48p9CadNCV6wq33esKtJ9z6jLss3V_yR9uD_7fyAbcYfpwNUL58D5B0dqHQAh8SuEH7GP6X_xfa7ZCX</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2942190309</pqid></control><display><type>article</type><title>Adipose Tissue and Umbilical Cord Tissue: Potential Sources of Mesenchymal Stem Cells for Liver Fibrosis Treatment</title><source>Alma/SFX Local Collection</source><creator>Ghufran, Hafiz ; Azam, Maryam ; Mehmood, Azra ; Umair, Muhammad ; Baig, Maria T. ; Tasneem, Saba ; Butt, Hira ; Riazuddin, Sheikh</creator><creatorcontrib>Ghufran, Hafiz ; Azam, Maryam ; Mehmood, Azra ; Umair, Muhammad ; Baig, Maria T. ; Tasneem, Saba ; Butt, Hira ; Riazuddin, Sheikh</creatorcontrib><description>Mesenchymal stem cells (MSCs) are potential alternatives for liver fibrosis treatment; however, their optimal sources remain uncertain. This study compares the ex-vivo expansion characteristics of MSCs obtained from adipose tissue (AT) and umbilical cord (UC) and assesses their therapeutic potential for liver fibrosis treatment.
Since MSCs from early to mid-passage numbers (P2–P6) are preferable for cellular therapy, we investigated the growth kinetics of AT-MSCs and UC-MSCs up to P6 and evaluated their therapeutic effects in a rat model of liver fibrosis induced by diethylnitrosamine.
Results from the expansion studies demonstrated that both cell types exhibited bona fide characteristics of MSCs, including surface antigens, pluripotent gene expression, and differentiation potential. However, AT-MSCs demonstrated a shorter doubling time (58.2 ± 7.3 vs. 82.3 ± 4.3 h; P < 0.01) and a higher population doubling level (10.1 ± 0.7 vs. 8.2 ± 0.3; P < 0.01) compared to UC-MSCs, resulting in more cellular yield (230 ± 9.0 vs. 175 ± 13.2 million) in less time. Animal studies demonstrated that both MSC types significantly reduced liver fibrosis (P < 0.05 vs. the control group) while also improving liver function and downregulating fibrosis-associated gene expression.
AT-MSCs and UC-MSCs effectively reduce liver fibrosis. However, adipose cultures display an advantage by yielding a higher number of MSCs in a shorter duration, rendering them a viable choice for scenarios requiring immediate single-dose administration, often encountered in clinical settings.
[Display omitted]</description><identifier>ISSN: 0973-6883</identifier><identifier>EISSN: 2213-3453</identifier><identifier>DOI: 10.1016/j.jceh.2024.101364</identifier><identifier>PMID: 38449506</identifier><language>eng</language><publisher>India: Elsevier B.V</publisher><subject>adipose tissue ; cellular therapy ; liver fibrosis ; mesenchymal stem cells ; umbilical cord</subject><ispartof>Journal of clinical and experimental hepatology, 2024-07, Vol.14 (4), p.101364-101364, Article 101364</ispartof><rights>2024 Indian National Association for Study of the Liver</rights><rights>2024 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-cbd998b7eac04d4097ef138e3ab713e06733d67a78d775b81f6274e203c7bb043</citedby><cites>FETCH-LOGICAL-c356t-cbd998b7eac04d4097ef138e3ab713e06733d67a78d775b81f6274e203c7bb043</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38449506$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ghufran, Hafiz</creatorcontrib><creatorcontrib>Azam, Maryam</creatorcontrib><creatorcontrib>Mehmood, Azra</creatorcontrib><creatorcontrib>Umair, Muhammad</creatorcontrib><creatorcontrib>Baig, Maria T.</creatorcontrib><creatorcontrib>Tasneem, Saba</creatorcontrib><creatorcontrib>Butt, Hira</creatorcontrib><creatorcontrib>Riazuddin, Sheikh</creatorcontrib><title>Adipose Tissue and Umbilical Cord Tissue: Potential Sources of Mesenchymal Stem Cells for Liver Fibrosis Treatment</title><title>Journal of clinical and experimental hepatology</title><addtitle>J Clin Exp Hepatol</addtitle><description>Mesenchymal stem cells (MSCs) are potential alternatives for liver fibrosis treatment; however, their optimal sources remain uncertain. This study compares the ex-vivo expansion characteristics of MSCs obtained from adipose tissue (AT) and umbilical cord (UC) and assesses their therapeutic potential for liver fibrosis treatment.
Since MSCs from early to mid-passage numbers (P2–P6) are preferable for cellular therapy, we investigated the growth kinetics of AT-MSCs and UC-MSCs up to P6 and evaluated their therapeutic effects in a rat model of liver fibrosis induced by diethylnitrosamine.
Results from the expansion studies demonstrated that both cell types exhibited bona fide characteristics of MSCs, including surface antigens, pluripotent gene expression, and differentiation potential. However, AT-MSCs demonstrated a shorter doubling time (58.2 ± 7.3 vs. 82.3 ± 4.3 h; P < 0.01) and a higher population doubling level (10.1 ± 0.7 vs. 8.2 ± 0.3; P < 0.01) compared to UC-MSCs, resulting in more cellular yield (230 ± 9.0 vs. 175 ± 13.2 million) in less time. Animal studies demonstrated that both MSC types significantly reduced liver fibrosis (P < 0.05 vs. the control group) while also improving liver function and downregulating fibrosis-associated gene expression.
AT-MSCs and UC-MSCs effectively reduce liver fibrosis. However, adipose cultures display an advantage by yielding a higher number of MSCs in a shorter duration, rendering them a viable choice for scenarios requiring immediate single-dose administration, often encountered in clinical settings.
[Display omitted]</description><subject>adipose tissue</subject><subject>cellular therapy</subject><subject>liver fibrosis</subject><subject>mesenchymal stem cells</subject><subject>umbilical cord</subject><issn>0973-6883</issn><issn>2213-3453</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kE1rGzEQhkVoaIyTP9BD0LGXdfVlabf0YkydFhwSiHMW-pglMruWK-0G_O-rxU6PncvAO--8zDwIfaFkQQmV3_aLvYO3BSNMTAKX4grNGKO84mLJP6EZaRSvZF3zG3SX856UksVM2Gd0w2shmiWRM5RWPhxjBrwLOY-AzcHj196GLjjT4XVM_jL5jp_jAIchFPkljslBxrHFj5Dh4N5O_SQP0OM1dF3GbUx4G94h4U2wKeaQ8S6BGfqScIuuW9NluLv0OXrd_Nytf1Xbp4ff69W2cnwph8pZ3zS1VWAcEV6Ud6ClvAZurKIciFSce6mMqr1SS1vTVjIlgBHulLVE8Dn6es49pvhnhDzoPmRXzjMHiGPWrBGMNoSTpljZ2erKrTlBq48p9CadNCV6wq33esKtJ9z6jLss3V_yR9uD_7fyAbcYfpwNUL58D5B0dqHQAh8SuEH7GP6X_xfa7ZCX</recordid><startdate>202407</startdate><enddate>202407</enddate><creator>Ghufran, Hafiz</creator><creator>Azam, Maryam</creator><creator>Mehmood, Azra</creator><creator>Umair, Muhammad</creator><creator>Baig, Maria T.</creator><creator>Tasneem, Saba</creator><creator>Butt, Hira</creator><creator>Riazuddin, Sheikh</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202407</creationdate><title>Adipose Tissue and Umbilical Cord Tissue: Potential Sources of Mesenchymal Stem Cells for Liver Fibrosis Treatment</title><author>Ghufran, Hafiz ; Azam, Maryam ; Mehmood, Azra ; Umair, Muhammad ; Baig, Maria T. ; Tasneem, Saba ; Butt, Hira ; Riazuddin, Sheikh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-cbd998b7eac04d4097ef138e3ab713e06733d67a78d775b81f6274e203c7bb043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>adipose tissue</topic><topic>cellular therapy</topic><topic>liver fibrosis</topic><topic>mesenchymal stem cells</topic><topic>umbilical cord</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ghufran, Hafiz</creatorcontrib><creatorcontrib>Azam, Maryam</creatorcontrib><creatorcontrib>Mehmood, Azra</creatorcontrib><creatorcontrib>Umair, Muhammad</creatorcontrib><creatorcontrib>Baig, Maria T.</creatorcontrib><creatorcontrib>Tasneem, Saba</creatorcontrib><creatorcontrib>Butt, Hira</creatorcontrib><creatorcontrib>Riazuddin, Sheikh</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical and experimental hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ghufran, Hafiz</au><au>Azam, Maryam</au><au>Mehmood, Azra</au><au>Umair, Muhammad</au><au>Baig, Maria T.</au><au>Tasneem, Saba</au><au>Butt, Hira</au><au>Riazuddin, Sheikh</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adipose Tissue and Umbilical Cord Tissue: Potential Sources of Mesenchymal Stem Cells for Liver Fibrosis Treatment</atitle><jtitle>Journal of clinical and experimental hepatology</jtitle><addtitle>J Clin Exp Hepatol</addtitle><date>2024-07</date><risdate>2024</risdate><volume>14</volume><issue>4</issue><spage>101364</spage><epage>101364</epage><pages>101364-101364</pages><artnum>101364</artnum><issn>0973-6883</issn><eissn>2213-3453</eissn><abstract>Mesenchymal stem cells (MSCs) are potential alternatives for liver fibrosis treatment; however, their optimal sources remain uncertain. This study compares the ex-vivo expansion characteristics of MSCs obtained from adipose tissue (AT) and umbilical cord (UC) and assesses their therapeutic potential for liver fibrosis treatment.
Since MSCs from early to mid-passage numbers (P2–P6) are preferable for cellular therapy, we investigated the growth kinetics of AT-MSCs and UC-MSCs up to P6 and evaluated their therapeutic effects in a rat model of liver fibrosis induced by diethylnitrosamine.
Results from the expansion studies demonstrated that both cell types exhibited bona fide characteristics of MSCs, including surface antigens, pluripotent gene expression, and differentiation potential. However, AT-MSCs demonstrated a shorter doubling time (58.2 ± 7.3 vs. 82.3 ± 4.3 h; P < 0.01) and a higher population doubling level (10.1 ± 0.7 vs. 8.2 ± 0.3; P < 0.01) compared to UC-MSCs, resulting in more cellular yield (230 ± 9.0 vs. 175 ± 13.2 million) in less time. Animal studies demonstrated that both MSC types significantly reduced liver fibrosis (P < 0.05 vs. the control group) while also improving liver function and downregulating fibrosis-associated gene expression.
AT-MSCs and UC-MSCs effectively reduce liver fibrosis. However, adipose cultures display an advantage by yielding a higher number of MSCs in a shorter duration, rendering them a viable choice for scenarios requiring immediate single-dose administration, often encountered in clinical settings.
[Display omitted]</abstract><cop>India</cop><pub>Elsevier B.V</pub><pmid>38449506</pmid><doi>10.1016/j.jceh.2024.101364</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0973-6883 |
| ispartof | Journal of clinical and experimental hepatology, 2024-07, Vol.14 (4), p.101364-101364, Article 101364 |
| issn | 0973-6883 2213-3453 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2942190309 |
| source | Alma/SFX Local Collection |
| subjects | adipose tissue cellular therapy liver fibrosis mesenchymal stem cells umbilical cord |
| title | Adipose Tissue and Umbilical Cord Tissue: Potential Sources of Mesenchymal Stem Cells for Liver Fibrosis Treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T16%3A47%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adipose%20Tissue%20and%20Umbilical%20Cord%20Tissue:%20Potential%20Sources%20of%20Mesenchymal%20Stem%20Cells%20for%20Liver%20Fibrosis%20Treatment&rft.jtitle=Journal%20of%20clinical%20and%20experimental%20hepatology&rft.au=Ghufran,%20Hafiz&rft.date=2024-07&rft.volume=14&rft.issue=4&rft.spage=101364&rft.epage=101364&rft.pages=101364-101364&rft.artnum=101364&rft.issn=0973-6883&rft.eissn=2213-3453&rft_id=info:doi/10.1016/j.jceh.2024.101364&rft_dat=%3Cproquest_cross%3E2942190309%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2942190309&rft_id=info:pmid/38449506&rft_els_id=S0973688324000215&rfr_iscdi=true |